Lv6
1812 积分 2023-03-05 加入
Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight
10天前
已完结
In vitro prediction of the immunogenicity of therapeutic proteins: state of the art and current challenges and perspectives
10天前
已完结
Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan
1个月前
已完结
Retinal Vasculopathy and Choroiditis after Pegcetacoplan Injection
1个月前
已完结
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events
1个月前
已完结
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
1个月前
已完结
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
4个月前
已完结
Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics
4个月前
已完结
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
4个月前
已完结
ImmunoStruct enables multimodal deep learning for immunogenicity prediction
5个月前
已完结
皖公网安备34019202002308
